Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
This study is a single arm phase II trial including 53 patients with T2N2-3M0、T3-4N0-3M0（III-IV） head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive neo-adjvuant Camrelizumab combined with cisplatin and Nab-paclitaxel.

This proposed study will evaluate the efficacy and safety of preoperative administration of Camrelizumab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) who are about to undergo surgery.
Head and Neck Squamous Cell Carcinoma
DRUG: Camrelizumab, nab-paclitaxel, cisplatin
ORR, overall response rate, 9 weeks
pCR, Pathological Complete Response, 9 weeks|MPR, Major Pathological Response, 9 weeks|DCR, Disease Control Rate, 9 weeks|PFS, Progression-free survival, 2 years|OS, overall survival, 5 years|Adverse events graded by CTCAE v5.0, Percentage of adverse events that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0)., 90 days after the first dose of study treatment
In this study, eligible subject will be enrolled into study arm to accept study treatment. Objective response rate will be the primary outcome measures.